GLP-1 Drug Lawsuits: Allegations of Undisclosed Blindness and Organ Damage Risks

Allegations Against GLP-1 Drug Manufacturers

• ⚖️ Thousands of patients are suing manufacturers of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, alleging they were not adequately warned about serious health risks.
• ⚠️ Plaintiffs claim these drugs have led to severe conditions including blindness (specifically NIO), severe gastrointestinal injuries, necrotizing pancreatitis, and even death from bowel conditions.

The Issue of Informed Consent

• 💡 Attorney Jonathan Orent argues that drugmakers have failed to sufficiently inform U.S. doctors about the full risk-benefit profile of these medications.
• 🗣️ This lack of information limits physicians' ability to have informed discussions with patients, thereby removing patient choice.
• 🇪🇺 Notably, European labels for some of these drugs, like Ozempic and Wegovy, do include warnings about the risk of blindness.

Proving Causation and Adverse Events

• 🔬 Lawyers rely on large-scale studies involving tens of thousands of people to identify increased rates of harm associated with GLP-1 drugs.
• 📊 These studies track individuals over time to establish correlations between drug use and conditions like NIO blindness, which is rare in the general population but appears more frequently in users of these drugs.
• 🩺 The legal strategy involves demonstrating these correlations to prove the link between the drugs and the severe adverse events experienced by clients.